Is there a relationship between baseline and treatment-associated changes in [H]-IMI platelet binding and clinical response in major depression?

Tollefson, Gary D.; Heiligenstein, John H.; Tollefson, Sherrie L.; Birkett, Martin; Knight, David L; Nemeroff, Charles B.

doi:10.1016/s0893-133x(96)80058-3

Cited by 10 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, although low B max values may persist for a considerable time after clinical improvement during and after imipramine treatment, long-term increases in B max values can follow complete remission and the B max values can remain elevated even after imipramine has been discontinued for 4 weeks (Suranyi-Cadotte et al, 1984). These results and others (Berrettini et al, 1982;Langer et al, 1987;Tollefson et al, 1996) have led to the suggestion that the reduced density of SERTs may be a state-dependent marker of depression, though this interpretation is not universally accepted. Indeed, whether platelet SERTs can be regulated by central or peripheral mechanisms is unclear.…”

Section: Introductionmentioning

confidence: 99%

The serotonin transporter and depression

Owens¹,

Nemeroff²

1998

Depress. Anxiety

102

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The serotonin transporter and depression

Owens¹,

Nemeroff²

1998

Depress. Anxiety

102

View full text Add to dashboard Cite

“…Not RCT Kroenke 2001 No outcome data available Massana 1998 Overview. Not RCT Patris 1996 Secondary publication of Bougerol 1997 Roose 1994 Schmidt 1999 Long-term treatment of depression Silverstone 2001 Comorbidity of major depressive disorder and generalized anxiety disorder Simon 1996 Not meeting inclusion criteria Simon 1998 Not meeting inclusion criteria Simon 1999 Not meeting inclusion criteria Strik 1998 No outcome data available Thase 2001 Pooled analysis of eight studies. Tollefson 1996 Sub-group analysis of Tollefson 1994 …”

Section: Characteristics Of Included Studies [Ordered By Study Id]mentioning

confidence: 99%

Fluoxetine versus other types of pharmacotherapy for depression

Cipriani

Brambilla

Furukawa

et al. 2005

Cochrane Database of Systematic Reviews

107

View full text Add to dashboard Cite

There are statistically significant differences in terms of efficacy and tolerability between fluoxetine and certain ADs, but the clinical meaning of these differences is uncertain, and no definitive implications for clinical practice can be drawn. From a clinical point of view the analysis of antidepressants' safety profile (adverse effect and suicide risk) remains of crucial importance and more reliable data about these outcomes are needed. Waiting for more robust evidence, treatment decisions should be based on considerations of clinical history, drug toxicity, patient acceptability, and cost. We need for large, pragmatic trials, enrolling heterogeneous populations of patients with depression to generate clinically relevant information on the benefits and harms of competitive pharmacological options. A meta-analysis of individual patient data from the randomised trials is clearly necessary.

show abstract

“…Studies using other platelet markers have also shown changes with treatment. Platelet [ 3 H]‐imipramine binding to the serotonin uptake site has been shown to correlate with treatment response to fluoxetine (35). Corroborative findings report [ 3 H]‐imipramine binding (21) and platelet serotonin levels (36) are predictive of a response to paroxetine treatment.…”

Section: State or Trait Marker Statusmentioning

confidence: 99%

The platelet window: examining receptor regulated second messenger processes in psychosis and depression

Berk

Malhi

2003

Acta Neuropsychiatr.

View full text Add to dashboard Cite

Peripheral markers of psychiatric illness provide a potentially important window into the pathophysiology of a number of psychiatric illnesses. Direct access to pathophysiological processes is fraught with difficulty. However, receptor-regulated second messenger-mediated calcium shifts are an accessible and practical method by which to examine changes in a clinical population. This is possible because platelets and neurons share some physiological features. The platelet intracellular calcium response to receptor stimulation has previously been used as a peripheral marker of psychiatric illness across a range of neurotransmitters, including serotonin, dopamine and glutamate. This review considers the specificity and selectivity of this response and its use in psychotic and mood disorders.

show abstract

Is there a relationship between baseline and treatment-associated changes in [H]-IMI platelet binding and clinical response in major depression?

Abstract: It. peripheral model for tlJe central 5-HT

Cited by 10 publications

References 33 publications

The serotonin transporter and depression

The serotonin transporter and depression

Fluoxetine versus other types of pharmacotherapy for depression

The platelet window: examining receptor regulated second messenger processes in psychosis and depression

Contact Info

Product

Resources

About